A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes us one of the most rewarding employers in our field.
Aurigene is a Bangalore based world-class drug discovery company with integrated capabilities for discovery and development of novel small molecule drugs.Aurigene provides Drug Discovery Services for Lead Generation/ Lead Optimization. The Business Model involves collaborative Drug Discovery with partners, on a risk- and reward-sharing basis. Typical Aurigene projects involve starting with a partner’s target protein and delivering an Optimized Lead, ready to go into clinical development.Aurigene employs both Structure Guided Drug Design (SGDD) and conventional Screening technologies for Drug Discovery. SGDD involves structural screening, computational chemistry aided ligand design, mining and screening of novel chemical entities, thus providing direction for Lead Discovery and Medicinal Chemistry. Early animal work involving ADME and Toxicity improves the probability of success. The approach helps in identifying the challenges at a very early stage and helps in setting a road map for the next steps in the process, thus shortening the overall project timelines and thereby mitigating risks.Aurigene is also identifying and building a portfolio of product opportunities focused on metabolic disorders, cardiovascular diseases, oncology and inflammatory diseases. Programs are chosen for significant unmet needs, and start with validated disease targets having well-defined roadmaps for clinical development. These are projects specifically designed for partnering with Pharma and Discovery Biotech companies.Target focus includes Kinases, Proteases, Nuclear Hormone Receptors and G-Protein Coupled Receptors.Using the strength of its technology and approach, Aurigene is able to provide novel solutions; its capabilities include significant speed and cost-effective innovation, coupled with the ability to rapidly scale-up scientific capabilities.Aurigene is founded by Dr Reddy’s Laboratories Limited (DRL). DRL is listed both on the New York Stock Exchange (NYSE) and Bombay Stock Exchange (BSE) with significant operations in USA and Europe.
Aurigene is a Bangalore based world-class drug discovery company with integrated capabilities for discovery and development of novel small molecule drugs.Aurigene provides Drug Discovery Services for Lead Generation/ Lead Optimization. The Business Model involves collaborative Drug Discovery with partners, on a risk- and reward-sharing basis. Typical Aurigene projects involve starting with a partner’s target protein and delivering an Optimized Lead, ready to go into clinical development.Aurigene employs both Structure Guided Drug Design (SGDD) and conventional Screening technologies for Drug Discovery. SGDD involves structural screening, computational chemistry aided ligand design, mining and screening of novel chemical entities, thus providing direction for Lead Discovery and Medicinal Chemistry. Early animal work involving ADME and Toxicity improves the probability of success. The approach helps in identifying the challenges at a very early stage and helps in setting a road map for the next steps in the process, thus shortening the overall project timelines and thereby mitigating risks.
Aurigene is a Bangalore based world-class drug discovery company with integrated capabilities for discovery and development of novel small molecule drugs.Aurigene provides Drug Discovery Services for Lead Generation/ Lead Optimization. The Business Model involves collaborative Drug Discovery with partners, on a risk- and reward-sharing basis. Typical Aurigene projects involve starting with a partner’s target protein and delivering an Optimized Lead, ready to go into clinical development.Aurigene employs both Structure Guided Drug Design (SGDD) and conventional Screening technologies for Drug Discovery. SGDD involves structural screening, computational chemistry aided ligand design, mining and screening of novel chemical entities, thus providing direction for Lead Discovery and Medicinal Chemistry. Early animal work involving ADME and Toxicity improves the probability of success. The approach helps in identifying the challenges at a very early stage and helps in setting a road map for the next steps in the process, thus shortening the overall project timelines and thereby mitigating risks.
ALLERGAN INC
Allergan Inc. a Fortune 500 company, with headquarters in Irvine, California, USA is an innovative, technology driven, global health care company that develops and commercializes products for the ophthalmic, neurological, dermatological and other specialty markets. Allergan markets products in over 101 countries worldwide through its global marketing and sales capabilities and delivers value to customers, satisfies unmet medical needs and improves patient’s lives through its discovery-to-development research programs.With global revenues of roughly $4bn in 2007, Allergan has tremendous focus on R&D with an investment of $700mn which is roughly 19.5% of revenues (highest percentage among pharma industry). Allergan operates 33 commercial locations, 4 world-class Research and Development facilities and 3 state-of-the-art manufacturing plants. AGN has many new chemical entities in phase 3 clinical stages and beyond of which 6 products are in the Glaucoma therapy area itself.Allergan is known for its operational efficiency and for this reason Allergan is rated by Forbes magazine (edition dated 20th December 2007) as the best managed company in the US in biotech/health business.